@article{article_815794, title={Oral Glucose-Lowering Agent Treatments in Type 2 Diabetes Mellitus}, journal={Turkish Journal of Internal Medicine}, volume={3}, pages={1–5}, year={2021}, DOI={10.46310/tjim.815794}, author={İmamoğlu, Şazi}, keywords={Type-2 diabetes, oral treatment, anti-diabetics}, abstract={Type 2 diabetes is manifested by impaired insulin secretion in pancreatic beta cells, increased glucagon secretion in alpha cells, and generally has a history of insulin resistance. The treatment of glucose metabolism disorder and the resulting hyperglycemia constitute an important part of the treatment of type 2 diabetes. Glycemic targets can be targeted with A1C <7% to reduce the risk of micro and macrovascular complications in eligible patients, and A1C <6.5% to reduce the risk of diabetic chronic renal failure and retinopathy in those with low risk of hypoglycemia. We can consider the treatment of hyperglycemia in two components; lifestyle changes and glucose-lowering agent therapy.}, number={1}, publisher={Nizameddin KOCA}